• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macros
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macros
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
Nairametrics
No Result
View All Result
Home Economy Socio Economic
Oxford COVID-19 vaccine

Covid-19: AstraZenca drugs aims to be ready for large-scale vaccination this year

Chike Olisah by Chike Olisah
3 years ago
in Socio Economic
Share on FacebookShare on TwitterShare on Linkedin

AstraZeneca, the leading COVID-19 vaccine candidate, has said that its coronavirus shots could be ready for large-scale vaccinations as early as this year, as it expects data from late-stage trials of the data to be also out this year.

The disclosure was made by the Chief Executive Officer of AstraZeneca Plc, Pascal Soriot, during a television interview with Bloomberg, where he dismissed reports of delays and production snags.

Sorot said the U.K. drugmaker is poised to unveil vaccine test results by year-end even after trials were slightly delayed over the summer as infection rates slowed in the northern hemisphere.

A recent resurgence has allowed scientists to gather the clinical data they need.

AstraZeneca, in collaboration with the University of Oxford, are keeping the vaccine in a frozen bulk state to preserve its shelf life while they await final test results.

Soriot in the interview said, “At the end of the day, we don’t yet know if the vaccine works,” adding that many questions remain, such as whether it will show results for everyone and for how long.

He said, “We would hope that large-scale vaccinations would be possible starting in January next year – possibly even December.”

Soriot’s remarks comes a day after Kate Bingham, Chair of the U.K. Vaccine Taskforce, said only 4 million doses of the shot would be available by the end of the year – far fewer than the 30 million that were due to be ready by September.

AstraZeneca said it’s confident it can begin supplying hundreds of millions of doses on a “rolling basis” once a shot is cleared.

It can be recalled that AstraZeneca has been at the forefront of efforts to develop a vaccine for the coronavirus pandemic, and its experimental shot could be one of the first to be approved globally, if successful.

Other drugmakers like Pfizer Inc. and Moderna Inc. are all seeking to deliver crucial test results on a vaccine in the coming weeks, with emergency clearance possible before the end of the year.

Astra has said it will sell the vaccine during the pandemic at a price tag of between $4 to $5, depending on local manufacturing charges.

The company said recently it would add as much as 20% to cover manufacturing costs and avoid any material impact on its finances.

Soriot also said Astra is incurring a bill in excess of $1 billion globally for expenses including clinical development.

What you should know

Nairametrics had reported that the vaccine candidate which is developed by AstraZeneca in collaboration with the University of Oxford, has produced a robust immune response in older adults and the elderly – those at highest risk of severe illness.

Astra and Oxford had also enrolled about 23,000 volunteers in vaccine trials globally, with plans to reach 50,000 once the U.S. arm has completed recruitment.

A U.K. government spokesperson said Thursday that “a vaccine will only be deployed once proven to be safe and effective,” and that the National Health Service was ready to start the vaccination program.


Download Nairametrics App for breaking news and market intelligence.
   
Tags: AstraZeneca PlcCovid-19 vaccine
Chike Olisah

Chike Olisah

Chike was a banker with over 11 years experience in retail and commercial banking, risk management, treasury portfolio management and relationship management. He also acquired some experience in financial management and do have some special interest in investment analysis and personal finance. He had stints with financial institutions like the former Intercontinental Bank and Fidelity Bank.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *







NM newsletters
HFM
Glo
Kwakol
Abbey
Zenth Bank
UBA
Mega Millions

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • WHO raises alarm over escalating tuberculosis infections in Borno
  • Nigeria records 226 crude oil theft incidents in one week – NNPCL
  • AcelorMittal to layoff 3500 South African workers as Steel demand falls

Follow us on social media:

Recent News

WHO , human rights ,pregnant women, HRP

WHO raises alarm over escalating tuberculosis infections in Borno

November 28, 2023
Crude oil theft

Nigeria records 226 crude oil theft incidents in one week – NNPCL

November 28, 2023
  • Download Nairametrics iOS App
  • Download Nairametrics Android App
  • Contact Us
  • Home
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Disclaimer
  • Ads Disclaimer

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macros
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
  • Login
  • Sign Up

© 2023 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In